NASDAQ:RVMD

Revolution Medicines Stock Forecast, Price & News

$28.02
+0.04 (+0.14 %)
(As of 07/27/2021 04:30 PM ET)
Add
Compare
Today's Range
$27.08
$28.32
50-Day Range
$27.98
$34.75
52-Week Range
$21.17
$56.18
Volume821,503 shs
Average Volume636,380 shs
Market Capitalization$2.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
30 days | 90 days | 365 days | Advanced Chart
Receive RVMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.


Revolution Medicines logo

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

454th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

62nd out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Revolution Medicines (NASDAQ:RVMD) Frequently Asked Questions

Is Revolution Medicines a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Revolution Medicines stock.
View analyst ratings for Revolution Medicines
or view top-rated stocks.

What stocks does MarketBeat like better than Revolution Medicines?

Wall Street analysts have given Revolution Medicines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Revolution Medicines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Revolution Medicines' next earnings date?

Revolution Medicines is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Revolution Medicines
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Monday, May, 10th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.01. The company had revenue of $10.13 million for the quarter, compared to analyst estimates of $10.10 million. Revolution Medicines had a negative trailing twelve-month return on equity of 24.40% and a negative net margin of 302.67%.
View Revolution Medicines' earnings history
.

How has Revolution Medicines' stock price been impacted by COVID-19 (Coronavirus)?

Revolution Medicines' stock was trading at $29.67 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RVMD stock has decreased by 5.6% and is now trading at $28.02.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RVMD?

3 brokers have issued twelve-month price targets for Revolution Medicines' shares. Their forecasts range from $44.00 to $55.00. On average, they anticipate Revolution Medicines' share price to reach $48.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts' price targets for Revolution Medicines
or view top-rated stocks among Wall Street analysts.

Who are Revolution Medicines' key executives?

Revolution Medicines' management team includes the following people:
  • Dr. Mark A. Goldsmith M.D., Ph.D., CEO, Pres & Chairman (Age 59, Pay $556.01k)
  • Ms. Margaret A. Horn, COO, Gen. Counsel & Sec. (Age 58, Pay $461.69k)
  • Dr. Stephen M. Kelsey M.D., FRCP, FRC Path., Pres of R&D (Age 60, Pay $466.21k)
  • Dr. Martin D. Burke, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael A. Fischbach, Academic Co-Founder & Member of Scientific Advisory Board (Age 40)
  • Dr. Kevan M. Shokat, Academic Co-Founder & Member of Scientific Advisory Board
  • Mr. Jack Anders, Sr. VP of Fin. & Principal Accounting Officer (Age 44)
  • Mr. David L. Pompliano, Founding Chief Scientific Officer
  • Mr. Walter Reiher Ph.D., Chief Information Officer
  • Ms. Luan M. Wilfong, Chief HR Officer

Who are some of Revolution Medicines' key competitors?

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

What is Revolution Medicines' stock symbol?

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

How do I buy shares of Revolution Medicines?

Shares of RVMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revolution Medicines' stock price today?

One share of RVMD stock can currently be purchased for approximately $28.02.

How much money does Revolution Medicines make?

Revolution Medicines has a market capitalization of $2.06 billion and generates $42.98 million in revenue each year. The company earns $-108,160,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Revolution Medicines have?

Revolution Medicines employs 131 workers across the globe.

What is Revolution Medicines' official website?

The official website for Revolution Medicines is www.revmed.com.

Where are Revolution Medicines' headquarters?

Revolution Medicines is headquartered at 700 Saginaw Drive, Redwood City CA, 94063.

How can I contact Revolution Medicines?

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The company can be reached via phone at 650-481-6801 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.